Live Breaking News & Updates on Sofinnova Investments Inc

Stay updated with breaking news from Sofinnova investments inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Erin Murphy , Nivi Nehra , Andrew Mckibben , Sam Martin , Naomi Eichenbaum , Frazier Life Sciences , European Commission , Securities Exchange , Mirum Pharmaceuticals Inc , Corporate Communications , Health Canada , Sofinnova Investments Inc , Exchange Commission , Travere Therapeutics Inc , Travere Therapeutics , Asset Purchase , Antitrust Improvements Act , Avidity Partners , Longitude Capital , Sofinnova Investments , Prescribing Information , Important Safety , Mirum Pharmaceuticals , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act ,

Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

03.08.2023 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for second quarter 2023 and provided a business update. “Our goal is to continue to bring life-changing medicines to patients with rare disease. Use of LIVMARLI in Alagille . ....

Sofinnova Investments Inc , European Commission , Mirum Pharmaceuticals Stock , Phepatology Communications , Frazier Life Sciences , Health Canada , Drug Administration , Mirum Pharmaceuticals Inc , Exchange Commission , Travere Therapeutics , Cerebrotendinous Xanthomatosis , Alagille Syndrome , New Drug Application , Prescription Drug User Fee Act , Avidity Partners , Sofinnova Investments , Call Details , Breakthrough Therapy , Fat Soluble Vitamin , Mirum Pharmaceuticals , Private Securities Litigation Reform Act , Consolidated Statement ,

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal®

Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestones

Mirum announces concurrent private placement of $210 million, funding upfront payment

Expands Mirum’s leadership in rare liver disease with two commercial products and a near-term Phase 3 label expansion opportunity

Advances Travere’s strategy to deliver new treatment standards from its pipeline of innovative medicines for rare diseases and strengthens financial foundation

Mirum to host conference call today, July 17, 2023, at 8:30 a.m. ET/5:30 a.m. PT ....

United States , Chris Peetz , Dunn Crutcher , Latham Watkins , Travere Therapeutics Inc , Frazier Life Sciences , Mirum Pharmaceuticals Inc , Morgan Stanley , Sofinnova Investments Inc , Mirum Pharmaceuticals , Travere Therapeutics , Avidity Partners , Longitude Capital , Sofinnova Investments , Ghost Conference , Bile Acid Transporters , Acid Binding Resins , Prescribing Information , Important Safety ,

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United States , Erin Murphy , Nivi Nehra , Dunn Crutcher , Latham Watkins , Naomi Eichenbaum , Andrew Mckibben , Chris Peetz , Sam Martin , Travere Therapeutics Inc , Securities Exchange , Sofinnova Investments Inc , Corporate Communications , Morgan Stanley , Mirum Pharmaceuticals Inc , Frazier Life Sciences , Mirum Pharmaceuticals , Travere Therapeutics , Avidity Partners , Longitude Capital , Sofinnova Investments , Ghost Conference , Bile Acid Transporters , Acid Binding Resins , Prescribing Information , Important Safety ,

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Sells $2,401,600.00 in Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) insider Kevin D. Bunker sold 80,000 shares of the company’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $30.02, for a total value of $2,401,600.00. Following the completion of the sale, the insider now owns 15,000 shares […] ....

Stifel Nicolaus , Sofinnova Investments Inc , Ensign Peak Advisors Inc , Zentalis Pharmaceuticals , Jefferies Financial Group , Zentalis Pharmaceuticals Price Performance , Zentalis Pharmaceuticals Inc , Quarter For Zentalis Pharmaceuticals , News Ratings For Zentalis Pharmaceuticals Daily , Barclays Plc , Opaleye Management Inc , Eventide Asset Management , Get Rating , Asset Management , Peak Advisors Inc , Zentalis Pharmaceuticals Daily , Nasdaq Zntl , Insider Trading , Nsider Trades ,